Billiontoone (NASDAQ:BLLN) Now Covered by BTIG Research

BTIG Research started coverage on shares of Billiontoone (NASDAQ:BLLN) in a research note issued to investors on Monday morning, MarketBeat reports. The firm issued a buy rating and a $160.00 target price on the stock.

Several other analysts also recently weighed in on the company. Stifel Nicolaus started coverage on Billiontoone in a research note on Monday. They issued a “buy” rating and a $145.00 price target on the stock. Wells Fargo & Company began coverage on Billiontoone in a report on Monday. They set an “equal weight” rating and a $110.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Billiontoone in a research report on Monday. They issued an “overweight” rating and a $150.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Billiontoone in a research report on Monday. They set a “hold” rating and a $117.00 price objective on the stock. Finally, William Blair initiated coverage on shares of Billiontoone in a research note on Monday. They set an “outperform” rating for the company. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

Billiontoone Trading Down 13.2%

Shares of Billiontoone stock opened at $113.04 on Monday. Billiontoone has a 1 year low of $88.00 and a 1 year high of $138.70.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.